RESUMO
BACKGROUND: Phase III clinical trials have documented the efficacy of the SARS-CoV-2 vaccines in preventing symptomatic COVID-19. Nonetheless, it is imperative to continue analyzing the clinical response to different vaccines in real-life studies. Our objective was to evaluate the effectiveness of five different vaccines in hospitalized patients with COVID-19 during the third COVID-19 outbreak in Mexico dominated by the Delta variant. METHODS: A test-negative case-control study was performed in nine tertiary-care hospitals for COVID-19. We estimated odds ratios (OR) adjusted by variables related a priori with the likelihood of SARS-CoV-2 infection and its severity. RESULTS: We studied 761 subjects, 371 cases, and 390 controls with a mean age of 53 years (SD, 17 years). Overall, 51% had a complete vaccination scheme, and an incomplete scheme (one dose from a scheme of two), 14%. After adjustment for age, gender, obesity, and diabetes mellitus, we found that the effectiveness of avoiding a SARS-CoV-2 infection when hospitalized with at least one vaccination dose was 71% (OR 0.29, 95% CI 0.19-0.45), that of an incomplete vaccination scheme, 67% (OR 0.33, 95% CI 0.18-0.62), and that of any complete vaccination scheme, 73% (OR 0.27, 95% CI 0.17-0.43). CONCLUSIONS: The SARS-CoV-2 vaccination program showed effectiveness in preventing SARS-CoV-2 infection in hospitalized patients during a Delta variant outbreak.
RESUMO
Fusarium species represent an opportunistic fungal pathogen. The data in Mexico about Fusarium infections in humans are scarce. Here, we present a retrospective series of patients with a confirmed diagnosis of fusariosis in eight different hospitals in Mexico from January 2010 to December 2019. The diagnosis of proven fusariosis was made according to the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium (EORT/MSG) criteria. A total of 49 cases were identified in our series. Most patients had burn injuries (49%), and 37% had hematological malignancies. Most patients had fire injuries (40%), followed by electric injuries (8%), febrile neutropenia (10%), and pancytopenia (6%). Patients had skin and soft tissue involvement in 49%, followed by blood culture isolation and biopsies from different sites of the body (lung, sinuses, bone tissue, and eyes). Febrile neutropenia (10%) and fungemia (8%) were the most common clinical syndromes in immunosuppressed patients. Most patients received monotherapy (67%), where voriconazole was used in 30% of the cases, followed by conventional amphotericin B (16%), and lipidic formulations of amphotericin B in 10% (either liposomal amphotericin B or amphotericin B lipid complex). Combination therapy was used in 20% of the cases, and the most common combination therapy was triazole plus any lipidic formulation of amphotericin B (10%). Mortality related to Fusarium infection occurred in 22% of patients. Fusariosis is a serious threat. Burn injuries and hematologic malignancies represent the most common causes of infection in this small series from Mexico.
This study describes the epidemiological characteristics of patients with fusariosis from a multicenter cohort in Mexico. These findings provide information from this invasive fungal disease that threatens different countries in Latin America.
Assuntos
Queimaduras , Neutropenia Febril , Fusariose , Fusarium , Neoplasias Hematológicas , Humanos , Fusariose/tratamento farmacológico , Fusariose/epidemiologia , Fusariose/veterinária , Anfotericina B/uso terapêutico , Antifúngicos/uso terapêutico , Estudos Retrospectivos , México/epidemiologia , Voriconazol/uso terapêutico , Neoplasias Hematológicas/veterinária , Queimaduras/complicações , Queimaduras/epidemiologia , Queimaduras/veterinária , Neutropenia Febril/tratamento farmacológico , Neutropenia Febril/veterináriaRESUMO
INTRODUCTION: The novel coronavirus pandemic (COVID-19) represents a major public health problem and it is key to find a treatment that reduces mortality. Our objective was to estimate whether treatment with 400 mg/day of Hydroxychloroquine for 10 days reduces in-hospital mortality in subjects with severe respiratory disease due to COVID-19 compared with placebo. MATERIAL AND METHODS: A double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of Hydroxychloroquine for the treatment of severe disease by COVID-19 through an intention-to-treat analysis. Eligible for the study were adults aged more than 18 years with COVID-19 confirmed by RT-PCR and lung injury requiring hospitalization with or without mechanical ventilation. Primary outcome was 30-day mortality. Secondary outcomes: days of mechanical ventilation, days of hospitalization and cumulative incidence of serious adverse events. RESULTS: A total of 214 patients with COVID-19 were recruited, randomized and analyzed. They were hypoxemic with a mean SpO2 of 65% ± 20, tachycardic (pulse rate 108±17 min-1) and tachypneic (32 ±10 min-1); 162 were under mechanical ventilation at randomization. Thirty-day mortality was similar in both groups (38% in Hydroxychloroquine vs. 41% in placebo, hazard ratio [HR] 0.88, 95% Confidence Interval [95%CI] 0.51-1.53). In the surviving participants, no significant difference was found in secondary outcomes. CONCLUSION: No beneficial effect or significant harm could be demonstrated in our randomized controlled trial including 214 patients, using relatively low doses of Hydroxychloroquine compared with placebo in hospitalized patients with severe COVID-19.
Assuntos
Tratamento Farmacológico da COVID-19 , Hidroxicloroquina/uso terapêutico , SARS-CoV-2/metabolismo , Adulto , Antivirais/uso terapêutico , COVID-19/metabolismo , COVID-19/mortalidade , Doenças Transmissíveis/epidemiologia , Método Duplo-Cego , Feminino , Hospitalização , Humanos , Masculino , México/epidemiologia , Pessoa de Meia-Idade , Respiração Artificial , Infecções Respiratórias/epidemiologia , SARS-CoV-2/patogenicidade , Resultado do TratamentoRESUMO
Dengue virus is the most prevalent arbovirus in Mexico, and although the diversity of this virus has been studied, the vast majority of sequences have been derived from viruses isolated from the human host. In this work, we aimed to sequence and to analyze DENVs derived from wild mosquitoes captured in Acapulco Guerrero, Mexico. We succeeded in determining three full genome sequences of such viruses and were able to compare them with other reported sequences from human and mosquito-derived DENVs. We found 15 nonsynonymous and 88 synonymous substitutions that were present more frequently in mosquito viruses than what would be expected by chance, although the limited number of genomes reported so far puts a constraint on the conclusions that can be derived from these analyses. Also, given the high depth of coverage attained in one of the genomes a variant analysis was carried out, finding 68 polymorphic sites in this genome. Interestingly, six of them corresponded to SNV that were detected as potentially differential between mosquitoes and humans, indicating that a that at least some positions may be maintained as polymorphic, which may facilitate host transmission.
Assuntos
Aedes/virologia , Vírus da Dengue/genética , Dengue/transmissão , Mosquitos Vetores/virologia , Animais , Genoma Viral/genética , Técnicas de Genotipagem , Humanos , México , Filogenia , Polimorfismo Genético , Sequenciamento Completo do GenomaRESUMO
In individuals with HIV/AIDS, 47% of the deaths are attributed to invasive fungal infections (IFIs), despite antiretroviral (ARV) therapy. This is a retrospective study carried out in the Hospital Regional de Alta Especialidad Oaxaca (HRAEO), southwest Mexico, where IFIs that occurred during 2016â»2017 are described. A total of 55 individuals were included. Histoplasmosis (36%) and possible-IFIs in neutropenic fever (20%) were the most frequent cases, followed by cryptococcosis (14%). The HIV/AIDS subpopulation corresponded with 26 cases (47%), all from an indigenous origin. The incidence of IFIs among them was 24% (95% CI = 15â»33%). The CD4+ T cells median was 35 cells/mL (IQR 12â»58). Four cases (15%) of unmasking IRIS were identified, three of histoplasmosis and one coccidioidomycosis. Co-infections were found in 52% (12/23), and tuberculosis in 50% (6/12) was the most frequent. The mortality rate was 48%. The general characteristics of the HIV individuals who died were atypical pneumonia (70% vs. 9%, p = 0.01), acute kidney injury, (70% vs. 9%, p = 0.008) and ICU stay (80% vs. 9%, p = 0.002). In conclusion, IFIs are diagnosed in one out of four individuals with HIV/AIDS along with other complicated infectious conditions, leading to major complications and a high mortality rate.
RESUMO
OBJECTIVES: The 2009-2010 influenza A (H1N1pdm09) pandemic caused substantial morbidity and mortality among young patients; however, mortality estimates have been confounded by regional differences in eligibility criteria and inclusion of selected populations. In 2013-2014, H1N1pdm09 became North America's dominant seasonal influenza strain. Our objective was to compare the baseline characteristics, resources, and treatments with outcomes among critically ill patients with influenza A (H1N1pdm09) in Mexican and Canadian hospitals in 2014 using consistent eligibility criteria. DESIGN: Observational study and a survey of available healthcare setting resources. SETTING: Twenty-one hospitals, 13 in Mexico and eight in Canada. PATIENTS: Critically ill patients with confirmed H1N1pdm09 during 2013-2014 influenza season. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The main outcome measures were 90-day mortality and independent predictors of mortality. Among 165 adult patients with H1N1pdm09-related critical illness between September 2013 and March 2014, mean age was 48.3 years, 64% were males, and nearly all influenza was community acquired. Patients were severely hypoxic (median PaO2-to-FIO2 ratio, 83 mm Hg), 97% received mechanical ventilation, with mean positive end-expiratory pressure of 14 cm H2O at the onset of critical illness and 26.7% received rescue oxygenation therapy with prone ventilation, extracorporeal life support, high-frequency oscillatory ventilation, or inhaled nitric oxide. At 90 days, mortality was 34.6% (13.9% in Canada vs 50.5% in Mexico, p < 0.0001). Independent predictors of mortality included lower presenting PaO2-to-FIO2 ratio (odds ratio, 0.89 per 10-point increase [95% CI, 0.80-0.99]), age (odds ratio, 1.49 per 10 yr increment [95% CI, 1.10-2.02]), and requiring critical care in Mexico (odds ratio, 7.76 [95% CI, 2.02-27.35]). ICUs in Canada generally had more beds, ventilators, healthcare personnel, and rescue oxygenation therapies. CONCLUSIONS: Influenza A (H1N1pdm09)-related critical illness still predominantly affects relatively young to middle-aged patients and is associated with severe hypoxemic respiratory failure. The local critical care system and available resources may be influential determinants of patient outcome.
Assuntos
Estado Terminal/terapia , Vírus da Influenza A Subtipo H1N1 , Influenza Humana/fisiopatologia , Influenza Humana/terapia , Unidades de Terapia Intensiva/estatística & dados numéricos , Corticosteroides/economia , Corticosteroides/uso terapêutico , Adulto , Idoso , Antivirais/economia , Antivirais/uso terapêutico , Canadá/epidemiologia , Estado Terminal/epidemiologia , Oxigenação por Membrana Extracorpórea/economia , Oxigenação por Membrana Extracorpórea/métodos , Feminino , Gastos em Saúde , Humanos , Influenza Humana/economia , Influenza Humana/epidemiologia , Masculino , México/epidemiologia , Pessoa de Meia-Idade , Respiração Artificial/economia , Respiração Artificial/métodos , Insuficiência Respiratória/fisiopatologia , Insuficiência Respiratória/terapiaRESUMO
BACKGROUND: We report results of the entomo-virological surveillance system in Aedes aegypti local populations performed by the Ministry of Health of Guerrero. METHODS: Indoor-adult Ae. aegypti collected at Acapulco, Zihuatanejo, Coyuca de Benitez and Atoyac de Alvarez (dry season, 2015) were processed for dengue virus (DENV) and chikungunya virus (CHIKV) using RT-PCR. RESULTS: We identified different seroptypes of DENV (2, 3 and 4), CHIKV and their co-circulation in field-caught mosquitoes across a significant geographic area. Pools of males were positive for CHIKV and DENV 3 and 4 suggesting vertical transmission. CONCLUSIONS: Entomo-virological surveillance in Guerrero has identified early circulation of CHIKV and DENV and provided a trigger for timely and focalized vector control actions.
Assuntos
Febre de Chikungunya/transmissão , Vírus Chikungunya/isolamento & purificação , Vírus da Dengue/isolamento & purificação , Dengue/transmissão , Transmissão Vertical de Doenças Infecciosas/estatística & dados numéricos , Aedes/virologia , Animais , Febre de Chikungunya/epidemiologia , Febre de Chikungunya/genética , Vírus Chikungunya/genética , Estudos Transversais , Dengue/epidemiologia , Dengue/genética , Vírus da Dengue/genética , Humanos , Insetos Vetores , México/epidemiologia , Reação em Cadeia da Polimerase em Tempo Real , Vigilância de Evento SentinelaRESUMO
We carried out dengue (DENV) and chikungunya virus (CHIKV) surveillance in wild populations of Aedes aegypti from Guerrero, Mexico, from 2012 to 2014 following a standard national protocol of the Mexican Dengue Control Program. A total of 284 pools (15-30 specimens/pool) of female mosquitoes were tested with real-time reverse transcriptase-polymerase chain reaction to detect DENV and CHIKV. We report for the 1st time the detection of CHIKV from field-collected mosquitoes at Acapulco and Juchitán in 2014. Results from DENV are also reported.
Assuntos
Aedes/virologia , Vírus Chikungunya/isolamento & purificação , Vírus da Dengue/isolamento & purificação , Animais , Feminino , México , Reação em Cadeia da Polimerase em Tempo Real , Reação em Cadeia da Polimerase Via Transcriptase ReversaRESUMO
BACKGROUND: Anal cancer has become one of the most common non-AIDS-defined tumors among Human Immunodeficiency Virus-positive (HIV+) individuals, and a rise in its incidence among HIV+ Men who have Sex with Men (MSM) has been shown, despite the introduction of Highly Active Anti-Retroviral Therapy (HAART). Human Papillomavirus (HPV) infections are highly prevalent among HIV+ MSM and recent studies have shown high rates of HPV-associated anal intraepithelial neoplasia (AIN) and anal cancer among this population. METHODS: In the present study we determined the prevalence and nature of HPV co-infections in the anal canal of 324 HIV+ MSM attending a high specialty medical center in Mexico City, DNA extraction and amplification with generic primers for HPV was performed, followed by detection of specific types and co-infections with INNO-Lipa, and identification of variants by amplification and sequencing of the E6 and LCR region of HPV 16. RESULTS: We found a very high prevalence of HPV infections among this cohort (86%), with more than one fourth of them (28%) positive for type 16. Among HPV16-positive patients, European variants were the most prevalent, followed by Asian-American ones. Among these individuals (HPV-16+), we identified co-infections with other 21 HPV types namely; 11, 51, 52, 6, 66, 68, 74, 18, 45, 35, 26, 44, 70, 53, 54, 82, 31, 33, 56, 58, 59. CONCLUSIONS: HIV+ MSM show a very high rate of HPV infections in the anal canal and those with type 16 exhibited a multiplicity of associated types. This study emphasizes the need for an early detection of HPV infections among HIV+ MSM in order to establish its utility to prevent anal neoplasia and cancer.
Assuntos
Canal Anal/virologia , DNA Viral/análise , Infecções por HIV/epidemiologia , Homossexualidade Masculina , Papillomaviridae/genética , Infecções por Papillomavirus/epidemiologia , Adulto , Terapia Antirretroviral de Alta Atividade , Neoplasias do Ânus/virologia , Carcinoma in Situ/virologia , Carcinoma de Células Escamosas/virologia , Coinfecção , Infecções por HIV/tratamento farmacológico , Soropositividade para HIV , Humanos , Incidência , Masculino , México , Pessoa de Meia-Idade , Epidemiologia Molecular , Papillomaviridae/isolamento & purificação , Infecções por Papillomavirus/virologia , PrevalênciaRESUMO
We carried out dengue virus surveillance in Aedes aegypti populations from 47 neighborhoods of Acapulco during the rainy season of 2011 following a standard national protocol and as an improvement of the entomological surveillance of the Mexican Dengue Control Program. A total of 4,146 Ae. aegypti adults collected indoors and/or emerged from eggs, larvae, or pupae from households with dengue reports (probable or confirmed cases), were grouped into pools and processed using a standardized serotype-specific 4-plex real-time reverse transcriptase-polymerase chain reaction assay. Overall, only 2 (0.9%) of 226 pools of Ae. aegypti adults (1 pool of adults emerged from field-collected larvae, and another of indoor-collected adults) were positive for dengue virus 1 (DENV-1). This is appears to be the 1st report of evidence on the vertical and transovarial transmission of DENV-1 in field-caught Ae. aegypti in Mexico.
Assuntos
Aedes/virologia , Vírus da Dengue/isolamento & purificação , Dengue/transmissão , Transmissão Vertical de Doenças Infecciosas , Animais , Feminino , Humanos , Masculino , México , Reação em Cadeia da Polimerase Via Transcriptase ReversaRESUMO
INTRODUCTION: congenital hearing loss is a serious health problem affecting 1 to 3 out of 1000 neonates, and is the most common cause of neurosensorial defect; hearing screening helps to identifying early permanent childhood hearing loss (HL). OBJECTIVE: to establish the percentage of hearing loss in newborns with and without risk factors through hearing screening. MATERIAL AND METHODS: by using a cross-sectional design, a group of neonates with risk factors and a group without risk factors were included in a two-stage hearing screening program. The otoacoustic emissions (OAEs) procedure was done in the first stage and the automated auditory brain stem response (AABR) procedure in the second stage. The latter was performed only in children with abnormal results in the OAE procedure. RESULTS: 518 newborns were included in the hearing screening procedures; 220 neonates with risk factors and 298 without risk factors. 35 had + OAE test and the ABBR procedure helped to confirm that 30 neonates had hearing loss, 26 had bilateral HL; 10 had asymmetric HL; 4 had unilateral HL and 5 were false positives. The AABR procedure ascertained 17 HL cases with a threshold > 40 dB (86 per 100,000), 11 cases (55 per 100,000) in the risk group and 6 (30 per 100,000) in the non-risk group (p < 0.05). The main risk factors were prematurity, craniofacial anomalies, mechanical ventilation, prescription of amikacin and cytomegalovirus infection. CONCLUSIONS: the two-stage hearing screening program ascertained that 5.7 % had HL. AABR (threshold > 40 dB) confirmed 17 (86 per 100,000) neonates with HL, which was more frequent in the risk group (5 %) than in the non-risk group (2 %; p < 0.05).